Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, July 17, 2019
[ Wed, Jul 17th 2019
] - WOPRAI
[ Wed, Jul 17th 2019
] - WOPRAI
[ Wed, Jul 17th 2019
] - WOPRAI
[ Wed, Jul 17th 2019
] - WOPRAI
[ Wed, Jul 17th 2019
] - WOPRAI
[ Wed, Jul 17th 2019
] - WOPRAI
[ Wed, Jul 17th 2019
] - WOPRAI
[ Wed, Jul 17th 2019
] - WOPRAI
[ Wed, Jul 17th 2019
] - WOPRAI
[ Wed, Jul 17th 2019
] - WOPRAI
[ Wed, Jul 17th 2019
] - WOPRAI
[ Wed, Jul 17th 2019
] - WOPRAI
Tue, July 16, 2019
[ Tue, Jul 16th 2019
] - WOPRAI
[ Tue, Jul 16th 2019
] - WOPRAI
[ Tue, Jul 16th 2019
] - WOPRAI
[ Tue, Jul 16th 2019
] - WOPRAI
[ Tue, Jul 16th 2019
] - WOPRAI
[ Tue, Jul 16th 2019
] - WOPRAI
[ Tue, Jul 16th 2019
] - WOPRAI
[ Tue, Jul 16th 2019
] - WOPRAI
[ Tue, Jul 16th 2019
] - WOPRAI
[ Tue, Jul 16th 2019
] - WOPRAI
David Lewis Maintained (ABT) at Buy with Increased Target to $93 on, Jul 16th, 2019
David Lewis of Morgan Stanley, Maintained "Abbott Laboratories" (ABT) at Buy with Increased Target from $85 to $93 on, Jul 16th, 2019.
David has made no other calls on ABT in the last 4 months.
There is 1 other peer that has a rating on ABT. Out of the 1 peers that are also analyzing ABT, 0 agree with David's Rating of Hold.
This is the rating of the analyst that currently disagrees with David
- Larry Biegelsen of "Wells Fargo" Maintained at Buy with Increased Target to $91 on, Thursday, June 13th, 2019
Similar Stocks and Investing Articles
[ Wed, Jan 02nd 2019
] - WOPRAI
[ Fri, Nov 30th 2018
] - WOPRAI
[ Thu, Oct 18th 2018
] - WOPRAI
[ Mon, Sep 24th 2018
] - WOPRAI
[ Tue, Apr 24th 2018
] - WOPRAI
[ Tue, Jan 30th 2018
] - WOPRAI
[ Wed, Aug 16th 2017
] - WOPRAI
[ Fri, Jul 21st 2017
] - WOPRAI
[ Fri, Jul 21st 2017
] - WOPRAI
[ Mon, Jul 10th 2017
] - WOPRAI